Does the media refer more to RARE or GRAL?

In the previous week, GRAIL had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 16 mentions for GRAIL and 8 mentions for Ultragenyx Pharmaceutical. GRAIL's average media sentiment score of 0.61 beat Ultragenyx Pharmaceutical's score of 0.17 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GRAIL 5 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RARE or COGT?

In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.51 beat Ultragenyx Pharmaceutical's score of 0.17 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RARE or TVTX?

In the previous week, Ultragenyx Pharmaceutical had 7 more articles in the media than Travere Therapeutics. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 1 mentions for Travere Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.17 beat Travere Therapeutics' score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ORKA or RARE?

In the previous week, Ultragenyx Pharmaceutical had 4 more articles in the media than Oruka Therapeutics. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 4 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.57 beat Ultragenyx Pharmaceutical's score of 0.17 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RARE or CRSP?

In the previous week, Ultragenyx Pharmaceutical and Ultragenyx Pharmaceutical both had 8 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.60 beat Ultragenyx Pharmaceutical's score of 0.17 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ultragenyx Pharmaceutical (RARE) Competitors

$14.46 -0.04 (-0.28%)

Closing price 04:00 PM Eastern

Extended Trading

$14.48 +0.02 (+0.14%)

As of 04:36 PM Eastern

Compare

RARE vs. GRAL, COGT, TVTX, ORKA, and CRSP

Should you buy Ultragenyx Pharmaceutical stock or one of its competitors? Ultragenyx Pharmaceutical's main competitors and comparable companies include GRAIL (GRAL), Cogent Biosciences (COGT), Travere Therapeutics (TVTX), Oruka Therapeutics (ORKA), and CRISPR Therapeutics (CRSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ultragenyx Pharmaceutical compare to GRAIL?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Ultragenyx Pharmaceutical has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, GRAIL has a beta of 2.83, meaning that its share price is 183% more volatile than the broader market.

GRAIL has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. GRAIL is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$717M	1.99	-$575M	-$5.84	N/A
GRAIL	$147.17M	46.77	-$408.35M	-$9.75	N/A

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 1.8% of GRAIL shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, GRAIL had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 16 mentions for GRAIL and 8 mentions for Ultragenyx Pharmaceutical. GRAIL's average media sentiment score of 0.61 beat Ultragenyx Pharmaceutical's score of 0.17 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRAIL	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ultragenyx Pharmaceutical has a net margin of -81.79% compared to GRAIL's net margin of -236.95%. Ultragenyx Pharmaceutical's return on equity of 0.00% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	N/A	-44.40%
GRAIL	-236.95%	-15.88%	-14.02%

Ultragenyx Pharmaceutical presently has a consensus price target of $34.58, indicating a potential upside of 138.48%. GRAIL has a consensus price target of $102.70, indicating a potential downside of 33.35%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Ultragenyx Pharmaceutical beats GRAIL on 11 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Cogent Biosciences?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.51 beat Ultragenyx Pharmaceutical's score of 0.17 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Cogent Biosciences has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Cogent Biosciences is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$717M	1.99	-$575M	-$5.84	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Cogent Biosciences has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Ultragenyx Pharmaceutical's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	N/A	-44.40%
Cogent Biosciences	N/A	-84.47%	-47.72%

Ultragenyx Pharmaceutical presently has a consensus price target of $34.58, indicating a potential upside of 138.48%. Cogent Biosciences has a consensus price target of $51.56, indicating a potential upside of 67.01%. Given Ultragenyx Pharmaceutical's higher probable upside, research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Ultragenyx Pharmaceutical beats Cogent Biosciences on 9 of the 15 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Travere Therapeutics?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

In the previous week, Ultragenyx Pharmaceutical had 7 more articles in the media than Travere Therapeutics. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 1 mentions for Travere Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.17 beat Travere Therapeutics' score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ultragenyx Pharmaceutical currently has a consensus target price of $34.58, suggesting a potential upside of 138.48%. Travere Therapeutics has a consensus target price of $69.50, suggesting a potential upside of 20.51%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Travere Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Travere Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$717M	1.99	-$575M	-$5.84	N/A
Travere Therapeutics	$490.73M	11.08	-$25.55M	-$0.46	N/A

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Travere Therapeutics has a net margin of -7.35% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Ultragenyx Pharmaceutical's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	N/A	-44.40%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Ultragenyx Pharmaceutical has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Summary

Ultragenyx Pharmaceutical beats Travere Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Ultragenyx Pharmaceutical had 4 more articles in the media than Oruka Therapeutics. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 4 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.57 beat Ultragenyx Pharmaceutical's score of 0.17 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oruka Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Ultragenyx Pharmaceutical	$717M	1.99	-$575M	-$5.84	N/A

Oruka Therapeutics has a beta of -0.37, meaning that its stock price is 137% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Oruka Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Ultragenyx Pharmaceutical's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Ultragenyx Pharmaceutical	-81.79%	N/A	-44.40%

Oruka Therapeutics presently has a consensus target price of $128.91, suggesting a potential upside of 52.77%. Ultragenyx Pharmaceutical has a consensus target price of $34.58, suggesting a potential upside of 138.48%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48

Summary

Oruka Therapeutics and Ultragenyx Pharmaceutical tied by winning 8 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to CRISPR Therapeutics?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Ultragenyx Pharmaceutical currently has a consensus price target of $34.58, indicating a potential upside of 138.48%. CRISPR Therapeutics has a consensus price target of $67.94, indicating a potential upside of 18.49%. Given Ultragenyx Pharmaceutical's higher possible upside, research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67

Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Ultragenyx Pharmaceutical has a net margin of -81.79% compared to CRISPR Therapeutics' net margin of -3,368.72%. Ultragenyx Pharmaceutical's return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	N/A	-44.40%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Ultragenyx Pharmaceutical has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$717M	1.99	-$575M	-$5.84	N/A
CRISPR Therapeutics	$11M	504.03	-$581.60M	-$4.76	N/A

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Ultragenyx Pharmaceutical and Ultragenyx Pharmaceutical both had 8 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.60 beat Ultragenyx Pharmaceutical's score of 0.17 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ultragenyx Pharmaceutical and CRISPR Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RARE vs. The Competition

Export

Metric	Ultragenyx Pharmaceutical	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.43B	$3.81B	$7.10B	$13.40B
Dividend Yield	N/A	3.65%	2.54%	17.38%
P/E Ratio	-2.48	13.23	273.67	26.20
Price / Sales	1.99	1,214.22	595.47	86.09
Price / Cash	N/A	39.04	27.22	34.74
Price / Book	-17.42	16.78	11.09	6.35
Net Income	-$575M	-$23.16M	$3.49B	$381.26M
7 Day Performance	-5.61%	-3.99%	-2.28%	-0.61%
1 Month Performance	-5.49%	-12.01%	-7.03%	-4.83%
1 Year Performance	-52.10%	14.71%	5.66%	1.12%

Ultragenyx Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RARE Ultragenyx Pharmaceutical	3.3908 of 5 stars	$14.46 -0.3%	$34.58 +139.1%	-53.5%	$1.43B	$717M	N/A	1,371
GRAL GRAIL	1.0459 of 5 stars	$132.63 +4.5%	$85.60 -35.5%	+135.1%	$5.67B	$147.17M	N/A	910	Gap Up
COGT Cogent Biosciences	2.5138 of 5 stars	$31.86 -1.4%	$51.56 +61.8%	+95.9%	$5.61B	N/A	N/A	258
TVTX Travere Therapeutics	1.9122 of 5 stars	$61.57 +3.6%	$69.50 +12.9%	+134.1%	$5.60B	$490.73M	N/A	497
ORKA Oruka Therapeutics	2.9716 of 5 stars	$84.19 -0.3%	$128.91 +53.1%	+326.4%	$5.59B	N/A	N/A	68

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RARE) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. GRAL, COGT, TVTX, ORKA, and CRSP

How does Ultragenyx Pharmaceutical compare to GRAIL?

Summary

How does Ultragenyx Pharmaceutical compare to Cogent Biosciences?

Summary

How does Ultragenyx Pharmaceutical compare to Travere Therapeutics?

Summary

How does Ultragenyx Pharmaceutical compare to Oruka Therapeutics?

Summary

How does Ultragenyx Pharmaceutical compare to CRISPR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. GRAL, COGT, TVTX, ORKA, and CRSP

How does Ultragenyx Pharmaceutical compare to GRAIL?

Which has more risk and volatility, RARE or GRAL?

Which has stronger valuation & earnings, RARE or GRAL?

Do insiders and institutionals have more ownership in RARE or GRAL?

Does the media refer more to RARE or GRAL?

Is RARE or GRAL more profitable?

Do analysts recommend RARE or GRAL?

Summary

How does Ultragenyx Pharmaceutical compare to Cogent Biosciences?

Do institutionals and insiders believe in RARE or COGT?

Does the media refer more to RARE or COGT?

Which has more volatility and risk, RARE or COGT?

Which has better valuation & earnings, RARE or COGT?

Is RARE or COGT more profitable?

Do analysts rate RARE or COGT?

Summary

How does Ultragenyx Pharmaceutical compare to Travere Therapeutics?

Does the media favor RARE or TVTX?

Do analysts prefer RARE or TVTX?

Which has preferable earnings & valuation, RARE or TVTX?

Do insiders and institutionals hold more shares of RARE or TVTX?

Is RARE or TVTX more profitable?

Which has more volatility & risk, RARE or TVTX?

Summary

How does Ultragenyx Pharmaceutical compare to Oruka Therapeutics?

Does the media prefer ORKA or RARE?

Which has higher earnings and valuation, ORKA or RARE?

Which has more volatility & risk, ORKA or RARE?

Do institutionals & insiders hold more shares of ORKA or RARE?

Is ORKA or RARE more profitable?

Do analysts rate ORKA or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to CRISPR Therapeutics?

Do analysts rate RARE or CRSP?

Which has more volatility & risk, RARE or CRSP?

Is RARE or CRSP more profitable?

Which has better earnings and valuation, RARE or CRSP?

Do insiders & institutionals hold more shares of RARE or CRSP?

Does the media prefer RARE or CRSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools